Biotherapeutics developer Avacta Group released its unaudited interim results for the period ended 31 January on Monday, reporting half-year revenues of £1.5m - up 16% year-on-year - comprising £0.7m from Avacta Life Sciences and £0.8m from Avacta Animal Health.
Biotechnology company Avacta Group has successfully concluded its initial study with next-generation antibody drug conjugates developer Glythera, leading to a licensing agreement between the two firms.
Avacta Group, the developer of 'Affimer' biotherapeutics and reagents, announced on Thursday that it has initiated a research collaboration with FIT Biotech to assess the effectiveness of developing gene therapies using its Affimer technology combined with FIT Biotech's 'gtGTU' platform.
Affimer biotherapeutics and research reagent developer Avacta Group announced that two unnamed leading US biotech companies had separately taken exclusive rights to Affimer reagents for research and development use, to support their respective drug development programmes.
Shares in Avacta Group are up more than 5% after it said the principal patent protecting the Affimer technology has been accepted for grant in the People's Republic of China.
Life science firm Avacta expects to have its first licensing deal for Affirmer, its biotherapeutics product, this year as its order book swelled.
Avacta Group announced a research collaboration with Memorial Sloan Kettering Cancer Center on Wednesday, to evaluate the use of the company's 'Affimer' technology in novel CAR-T cell-based immunotherapy.
Biotherapeutic, research and diagnostic reagent developer Avacta Group announced its preliminary results for the year to 31 July on Monday, with revenues and losses in line with market expectations.
Affimer biotherapeutics and research reagents developer Avacta Group announced positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules on Thursday.
A collaboration programme between AIM-listed Avacta and Leeds University has been awarded a £3.8m grant by the Medical Research Council.
European and US regulators handed down further patent decisions in favour of Avacta´s Affimer biotherapeutics and research reagents, helping the company to consolidate its intelectual property portfolio.
Life sciences company Avacta said on Monday that revenue for the year to the end of July grew by around 19% but losses nearly doubled due to a change in accounting policy.
Avacta, biotherapeutics and research agent developer, reported on Wednesday it had identified three proteins which could be used to develop the first tests to diagnose early stages of the Zika virus.
Avacta Group established what it saw as one of the last pieces in the management puzzle to get its products towards the market, appointing professors Terence Rabbitts, Paul Moss and Adrian Hayday to form the company's scientific advisory board on Monday.
Shares in Avacta Group surged over 25% on Monday, after the proprietary diagnostic tools provider said it had reached a deal with biotech group Moderna Therapeutics.
Avacta Group, a technology provider for life science markets, saw its full year losses narrow on healthier revenues.
Avacta Group: Numis lowers target price from 2p to 1.6p retaining its buy recommendation.
AstraZeneca: Deutsche Bank ups target price from 3950p to 4000p staying with its hold recommendation.
A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook.
Advanced Computer Software: Panmure Gordon ups target price from 139p to 155p and stays with its buy recommendation.